Clinical trials: Acute and chronic pain

Clinical Pain Management: Practice and Procedures, 2nd edition

Volumn , Issue , 2008, Pages 514-528

  Stubhaug, Audun ^a   Breivik, Harald ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85136739214     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b13562-42     Document Type: Chapter

References (66)

1. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Diseases. 1967; 20: 637-48.
2. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association. 1995; 273: 408-12.
3. Stubhaug A, Breivik H. Post-operative analgesic trials:some important issues. In: Breivik H (ed.). Post-operative pain management. Baillie’re’s Clinical Anaesthesiology:International Practice and Research 9. London: Baillie’re Tindall, 1995: 555-84.
4. Max MB. The design of clinical trials of pain treatment. In:Max MB, Lynn J. editors. Symptom research. Methods and opportunities. An interactive textbook. Last updated October 2003, cited February 2008. Available from: http:// symptomresearch.nih.gov/chapter_1/index.htm.
5. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. When placebo controlled trials are essential and equivalence trials are inadequate. British Medical Journal. 1998; 317:875-80.
6. Landow L. Current issues in clinical trial design: superiority versus equivalency studies. Anesthesiology. 2000; 92:1814-20.
7. Stubhaug A. Comparison of tramadol with morphine for post-operative pain following abdominal surgery. European Journal of Anaesthesiology. 1996; 13:416-17.
8. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the effects of oral and intramuscular administration of analgesics: pentazocine and phenazocine. Clinical Pharmacology and Therapeutics. 1968; 9: 582-97.
9. Owen H, Plummer JL, Armstrong I et al. Variables of patient-controlled analgesia. 1. Bolus size. Anaesthesia. 1989; 1: 7-10.
10. Max MB. Divergent traditions in analgesic clinical trials. Clinical Pharmacology and Therapeutics. 1994; 56:237-41.
11. Tallarida RJ, Stone DJ, Raffa RB. Efficient designs for studying synergistic drug combinations. Life Sciences. 1997; 61: 417-25.
12. Parkhouse J, Lambrechts W, Simpson BRJ. The incidence of postoperative pain. British Journal of Anaesthesia. 1961; 33: 345-53.
13. McQuay HJ, Bullingham RE, Moore RA et al. Some patients don’t need analgesics after surgery. Journal of the Royal Society of Medicine. 1982; 75: 705-08.
14. Rosseland LA, Stubhaug A. Gender is a confounding factor in pain trials: Women report more pain than men after arthroscopic surgery. Pain. 2004; 112: 248-53.
15. Turner JA, Deyo RA, Loeser JD et al. The importance of placebo effects in pain treatment and research. Journal of the American Medical Association. 1994; 271: 1609-14.
16. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human. Journal of the American Medical Association. 2000; 284:3043-45.
17. Altman DG, Bland JM. How to randomise. British Medical Journal (Clinical research ed.). 1999; 319: 703-04.
18. Meinert CL. Clinical trials. Design, conduct and analysis. New York: Oxford University Press, 1986.
19. Pocock SJ. Clinical trials. A practical approach. New York:John Wiley and Sons, 1983.
20. Altman DG, Bland JM. Treatment allocation by minimisation. British Medical Journal (Clinical research ed.). 2005; 330: 843.
21. Schulz KF. Randomised trials, human nature, and reporting guidelines. Lancet. 1996; 348: 596-8.
22. Pildal J, Hrobjartsson A, Jorgensen K et al. Impact of allocation concealment on conclusions drawn from metaanalyses of randomized trials. International Journal of Epidemiology. 2007; 36: 847-57.
23. Moher D, Schulz KF, Altman DG. The CONSORT statement:revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357: 1191-4.
24. Altman DG, Schulz KF, Moher D et al. CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials:explanation and elaboration. Annals of Internal Medicine. 2001; 134: 663-94.
25. Woolf CJ, Max MB. Mechanism-based pain diagnosis:issues for analgesic drug development. Anesthesiology. 2001; 95: 241-9.
26. Watson CP, Moulin D, Watt-Watson J et al. Controlledrelease oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003; 105: 71-78.
27. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain. 2007; 130:66-75.
28. Max MB, Schafer SC, Culnane M et al. Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clinical Pharmacology and Therapeutics. 1988; 43: 363-71.
29. Romundstad L, Breivik H, Niemi G et al. Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effectys. Acta Anaesthesiologica Scandinavica. 2004; 48:1223-31.
30. Hróbjartsson A, Forfang E, Haahr MT et al. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. International Journal of Epidemiology. 2007; 36: 654-63.
31. Gilron I, Orr E, Tu D et al. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. Pain. 2005; 113: 191-200.
32. Sriwatanakul K, Lasagna L, Cox C. Evaluation of current clinical trial methodology in analgesimetry based on experts’ opinions and analysis of several analgesic studies. Clinical Pharmacology and Therapeutics. 1983; 34:277-83.
33. Jones B, Kenward MG. Design and analysis of cross-over trials. London: Chapman and Hall, 1989.
34. Nielsen CS, Stubhaug A, Price DD et al. Individual differences in pain sensitivity: Genetic and environmental contributions. Pain. 2008; 136: 21-9.
35. Casarett D, Karlawish J, Sankar P et al. Designing pain research from the patients perspective: what trial end points are important to patients with chronic pain? Pain Medicine. 2001; 2: 309-16.
36. Dworkin RH, Turk DC, Farrar JT et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005; 113: 9-19.
37. Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clinical Journal of Pain. 2000; 16: 22-8.
38. Price DD, Harkins SW, Baker C. Sensory-affective relationships among different types of clinical and experimental pain. Pain. 1987; 28: 297-307.
39. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987; 30: 191-7.
40. Stubhaug A, Breivik H, Eide PK et al. Mapping of punctuate hyperalgesia surrounding a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiologica Scandinavica. 1997; 41: 1124-32.
41. Gilron I, Max MB, Lee G et al. Effects of the AMPA/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clinical Pharmacology and Therapeutics. 2000; 68: 320-7.
42. Attal N, Brasseur L, Parker F et al. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. European Neurology. 1998; 40: 191-200.
43. Sjolund KF, Belfrage M, Karlsten R et al. Systemic adenosine infusion reduces the area of tactile allodynia in neuropathic pain following peripheral nerve injury: a multi-centre, placebo-controlled study. European Journal of Pain. 2001; 5: 199-207.
44. Jørum E, Warncke T, Stubhaug A. Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine; a double blind, cross-over comparison with alfentanil and placebo. Pain. 2003; 101: 229-35.
45. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. British Medical Journal (Clinical research ed.). 1990; 300:230-5.
46. Vickers AJ, Altman DJ. Statistics notes: Analysing controlled trials with baseline and follow up measurements. British Medical Journal (Clinical research ed.). 2001; 323: 1123-4.
47. Silverman DG, O’Connor TZ, Brull SJ. Integrated assessment of pain scores and rescue morphine use during studies of analgesic efficacy. Anesthesia and Analgesia. 1993; 77: 168-70.
48. Romundstad L, Breivik H, Roald H et al. Methylprednisolone reduces pain, emesis, and fatigue after breast augmentation surgery: a single-dose, randomized, parallel-group study with methylprednisolone 125 mg, parecoxib 40 mg, and placebo. Anesthesia and Analgesia. 2006; 102: 418-25.
49. Laska EM, Siegel C, Sunshine A. Onset and duration:measurement and analysis. Clinical Pharmacology and Therapeutics. 1991; 49: 1-5.
50. Bellamy N, Buchanan WW, Goldsmith CH et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. Journal of Rheumatology. 1988; 15: 1833-40.
51. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Annals of the Academy of Medicine of Singapore. 1994; 23: 129-38.
52. Beck AT, Ward CH, Mendelson M et al. An inventory for measuring depression. Archives of General Psychiatry. 1961; 4: 561-71.
53. McNair DM, Lorr M, Droppleman LF. Profile of mood states. San Diego, CA: Educational and Industrial Testing Service, 1971.
54. Turk DC, Dworkin RH, Burke LB et al. Developing patientreported outcome measures for pain clinical trials:IMMPACT recommendations. Pain. 2006; 125: 208-15.
55. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care. 1992; 30: 473-83.
56. Fredheim O, Kaasa S, Fayers P et al. Chronic nonmalignant pain patients report as poor health related quality of life as palliative cancer patients. Acta Anaesthesiologica Scandinavica. 2008; 52: 143-8.
57. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved:lessons from acute postoperative pain. Journal of Pain and Symptom Management. 1999; 18: 427-37.
58. Farrar JT, Portenoy RK, Berlin JA et al. Defining the clinically important difference in pain outcome measures. Pain. 2000; 88: 287-94.
59. Farrar JT, Young Jr JP, LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001; 94: 149-58.
60. Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain. 2008; 9: 105-21.
61. McQuay H, Moore A. An evidence-based resource for pain relief. Oxford: Oxford University Press, 1998.
62. Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. Journal of Pain and Symptom Management. 2006; 31:369-77.
63. Thaler HT, Friedlander-Klar H, Cirrincione C et al. A statistical approach to measuring analgesic response. In:Bond MR, Charlton J, Woolf C (eds). Proceedings of the VIth World Congress on Pain. Amsterdam: Elsevier, 1991:539-42.
64. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clinical Pharmacology and Therapeutics. 1995; 57: 6-15.
65. Lachin JM. Statistical considerations in the intentto-treat principle. Controlled Clinical Trials. 2000; 21:167-89.
66. De Angelis C, Drazen JM, Frizelle FA et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Annals of Internal Medicine. 2004; 141: 477-8.